These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26030078)

  • 1. 10 years after implementation of TRIPS obligations in India.
    Pawar MD
    Pharm Pat Anal; 2015; 4(3):147-59. PubMed ID: 26030078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Big-pharmaceuticalisation: clinical trials and Contract Research Organisations in India.
    Sariola S; Ravindran D; Kumar A; Jeffery R
    Soc Sci Med; 2015 Apr; 131():239-46. PubMed ID: 25476783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. With the help of a foreign ally: biopharmaceutical innovation in India after TRIPS.
    Angeli F
    Health Policy Plan; 2014 May; 29(3):280-91. PubMed ID: 23558959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals.
    Babovic S; Wasan KM
    J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fine print TRIPS up multinational and Indian companies.
    Frantz S
    Nat Rev Drug Discov; 2005 Feb; 4(2):94-5. PubMed ID: 15759327
    [No Abstract]   [Full Text] [Related]  

  • 6. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 27717949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of TRIPS on innovation and exports: a case study of the pharmaceutical industry in India.
    Malhotra P
    Indian J Med Ethics; 2008; 5(2):61-5. PubMed ID: 18624153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new patent regime and disease priorities in India.
    Gupta I; Guin P; Trivedi M
    Glob Public Health; 2013; 8(1):37-54. PubMed ID: 22845021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the legal regime of intellectual property protection in the pharmaceutical market.
    Pashkov VM; Golovanova IA; Olefir AA
    Wiad Lek; 2016; 69(3 pt 2):582-586. PubMed ID: 28478430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How do public health safeguards in Indian patent law affect pharmaceutical patenting in practice?
    Sampat BN; Amin T
    J Health Polit Policy Law; 2013 Aug; 38(4):735-55. PubMed ID: 23645877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
    Halliburton M
    Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharma industry in India.
    Sundaram VM
    Drug News Perspect; 2008; 21(1):59-63. PubMed ID: 18301810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging trends in contract research industry in India.
    Drabu S; Gupta A; Bhadauria A
    Contemp Clin Trials; 2010 Sep; 31(5):419-22. PubMed ID: 20609394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poverty, health & intellectual property rights with special reference to India.
    Satyanarayana K; Srivastava S
    Indian J Med Res; 2007 Oct; 126(4):390-406. PubMed ID: 18032814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India.
    Satyanarayana K; Srivastava S
    Open AIDS J; 2010 Jan; 4():41-53. PubMed ID: 20148091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States.
    Son KB; Lopert R; Gleeson D; Lee TJ
    Global Health; 2018 Oct; 14(1):101. PubMed ID: 30355313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trade, TRIPS, and pharmaceuticals.
    Smith RD; Correa C; Oh C
    Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Administrative Meter Maid: Using Inter Partes Review and Post-Grant Review to Curb Exclusivity Parking via the "Failure to Market" Provision of the Hatch-Waxman Act.
    Apel BT
    Mich Law Rev; 2015; 114(1):107-36. PubMed ID: 26394458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will the Modi government succumb to US and industry pressure to modify its pro-access pharmaceutical patent policy?
    Baker BK
    Expert Opin Ther Pat; 2015 Jun; 25(6):625-8. PubMed ID: 25704359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The balance between innovation and competition: the Hatch-Waxman Act, the 2003 Amendments, and beyond.
    Kelly C
    Food Drug Law J; 2011; 66(3):417-78, iii. PubMed ID: 24505856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.